The condition known as Central Retinal Artery Occlusion (CRAO) involves the blockage of blood flow in the central retinal artery of the eye, which may result in significant damage to the optic nerve and subsequent loss of vision. The occurrence of retinal edoema and pyknosis of ganglion cell nuclei has the potential to lead to severe injury to the optic nerve and retina, ultimately resulting in vision loss. In 1859, the first case of CRAO was described by Von Graefe; it has been recognised as a clinical entity ever since (1). The condition typically manifests at an average age of early 60s and exhibits a prevalence of roughly 1 per 100,000 individuals, with a higher incidence rate observed in males (2, 3). The severity of damage is commonly associated with the degree of retinal edoema, as well as the duration of the injury and the existence of collateral arteries, which also affect retinal recovery (4, 5).
Individuals who suffered from CRAO exhibited a significantly reduced lifespan of 5.5 years in comparison to their non-CRAO counterparts of similar age, whose life expectancy was estimated to be 15.4 years (6).
The ophthalmic artery's initial intraorbital branch, known as the central retinal artery, provides the retina with blood supply. It penetrates the optic nerve through the posterior region of the eye. CRAO is most frequently caused by carotid artery atherosclerosis. Nevertheless, among individuals who are below 40 years old, cardiogenic embolism stands out as the most predominant aetiology (7, 8). The typical manifestation of this condition is characterised by an abrupt onset of painless visual impairment that may be preceded by temporary episodes of visual loss, also known as amaurosis fugax. Patients with CRAO typically report experiencing total loss of vision. However, in instances where the cilioretinal artery is spared, macular sparing may be observed (8). Research has demonstrated that the likelihood of emboli originating from a cardiac source is notably elevated in individuals with a medical history of specific cardiac conditions, such as congenital heart disease, atrial fibrillation, valvular heart disease, and rheumatic heart disease (9). The timely detection and management of emboli or thrombi is crucial to prevent permanent visual impairment and irreversible harm. This may involve dislodgement or lysis interventions. As ischemia progresses, the retina undergoes necrosis, leading to vision loss and a yellow-white opaque appearance. Studies utilising experimental models have revealed that a duration of slightly over 90 minutes of complete central retinal artery occlusion results in irreversible damage to the retina (3).
Calcium emboli in one of the coronary arteries have been theorised to be the origin of the presenting symptoms of calcific aortic stenosis. These emboli are often small and silent if they occlude other arteries. However, the retinal circulation is distinctive in that it is obstructed by calcium microemboli, resulting in vision loss, which may be a sign of calcified aortic stenosis. A few of the reported patients had severe valvular stenosis without any symptoms. Moreover, the correlation between the location of calcification, the degree of valve stenosis, and calcific retinal embolism remains uncertain. Anatomical variability is present in approximately 15% of the population, where the cilioretinal artery plays a significant role in providing collateral circulation to the macula. The manifestations in such cases are generally less severe and the long-term prognosis is more favourable (10).
The clinical assessment commonly reveals unilateral vision loss accompanied by an abnormal afferent pupillary response. Visual acuity may vary only between finger counting and loss of eye perception. The presence of an amaurotic pupil (absence of constriction upon direct illumination) intact consensual light response, and an intact near response have been reported. Typically, extraocular eye movements, anterior chamber examinations, and intraocular pressure are within normal limits. A thorough fundoscopic examination is necessary to confirm the diagnosis of CRAO, and any patient presenting with symptoms concerning CRAO must have a comprehensive exam if there are no contraindications to mydriatic medications. Upon fundoscopic examination, the retina displays a diffuse pallor, accompanied by a central macular spot that exhibits a cherry red hue. The aforementioned location is a consequence of the conserved choroidal circulation that flows beneath the thin fovea (Fig. 1).
In addition, the arterioles may be narrowed or segmented. Among the various types of emboli, calcium emboli exhibit a white appearance, cholesterol emboli (also known as Hollenhorst plaques) display an orange hue, and platelet-fibrin emboli manifest as dull white. However, the visualisation of arteriolar emboli is infrequent (11).